Abstract
The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.
Original language | English (US) |
---|---|
Pages (from-to) | 92S-96S |
Journal | Seminars in cutaneous medicine and surgery |
Volume | 35 |
DOIs | |
State | Published - Jun 1 2016 |
Keywords
- Atopic dermatitis
- Crisaborole
- Dupilumab
- Interleukin inhibitors
- Petrolatum
- Skin barrier
ASJC Scopus subject areas
- Surgery
- Dermatology